Cipla Ltd — Q4 FY25
Cipla delivered a solid Q4 FY25 with revenue of INR 6,730 crore (+9% YoY) and EBITDA margin of 22.8% (+150bps YoY), driven by strong performance across One India (+8% YoY), Nort...
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY25
Generic Advair launch in late H1 FY26
Cipla plans to launch generic Advair from its US facility in late first half of FY26, with de-risking progressing as expected.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q3 FY25
FY25 EBITDA margin to exceed guidance
EBITDA for FY25 is trending higher than earlier guidance of 24.5%-25.5%, with Q3 margin at 28% but not sustainable.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1